Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers

International Journal of Cancer

Volumn 137, Issue 5, 2015, Pages 1136-1146

  Kotsopoulos, Joanne ^a   Lubinski, Jan ^b   Gronwald, Jacek ^b   Cybulski, Cezary ^b   Demsky, Rochelle ^c   Neuhausen, Susan L ^d   Kim Sing, Charmaine ^e   Tung, Nadine ^f   Friedman, Susan ^g   Senter, Leigha ^h   Weitzel, Jeffrey ^d   Karlan, Beth ⁱ   Moller, Pal ^j   Sun, Ping ^a   Narod, Steven A ^a  

^a WOMEN S COLLEGE HOSPITAL   (Canada)

^b POMERANIAN MEDICAL UNIVERSITY   (Poland)

^c UNIVERSITY OF TORONTO   (Canada)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^e BRITISH COLUMBIA CANCER AGENCY   (Canada)

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^g H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^h THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

ⁱ CEDARS SINAI MEDICAL CENTER   (United States)

^j OSLO UNIVERSITY HOSPITAL   (Norway)

more..

Author keywords

BRCA1; BRCA2; ovarian cancer; ovulation

Indexed keywords

ADULT; AGED; ARTICLE; BREAST FEEDING; CANCER PREVENTION; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; ETHNIC DIFFERENCE; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; ORAL CONTRACEPTIVE USE; OVARY CANCER; OVULATION; PARITY; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; CONTRACEPTION; GENETIC PREDISPOSITION; GENETICS; MUTATION; OVARIAN NEOPLASMS; PREGNANCY; QUESTIONNAIRE; RISK FACTOR; STATISTICAL MODEL;

BRCA1 PROTEIN; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN; BRCA2 PROTEIN, HUMAN;

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST FEEDING; CASE-CONTROL STUDIES; CONTRACEPTION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LOGISTIC MODELS; MUTATION; OVARIAN NEOPLASMS; OVULATION; PARITY; PREGNANCY; RISK FACTORS; SURVEYS AND QUESTIONNAIRES;

EID: 84931564561     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29386     Document Type: Article

References (45)

1. Antoniou A, Pharoah PD, Narod S, et al., Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72: 1117-30.
2. Ford D, Easton DF, Stratton M, et al., Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62: 676-89.
3. Risch HA, McLaughlin JR, Cole DE, et al., Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001; 68: 700-10.
4. Mavaddat N, Barrowdale D, Andrulis IL, et al., Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev 2012; 21: 134-47.
5. Finch AP, Lubinski J, Moller P, et al., Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol 2014; 32: 1547-53.
6. Moorman PG, Havrilesky LJ, Gierisch JM, et al., Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol 2013; 31: 4188-98.
7. McLaughlin JR, Risch HA, Lubinski J, et al., Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol 2007; 8: 26-34.
8. Beral V, Doll R, Hermon C, et al., Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87, 303 controls. Lancet 2008; 371: 303-14.
9. Antoniou AC, Rookus M, Andrieu N, et al., Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol Biomarkers Prev 2009; 18: 601-10.
10. Milne RL, Osorio A, Ramon y Cajal T, et al., Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 2010; 119: 221-32.
11. Friebel TM, Domchek SM, Rebbeck TR., Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis. J Natl Cancer Inst 2014; 106: dju235.
12. Fathalla MF., Incessant ovulation-a factor in ovarian neoplasia? Lancet 1971; 2: 163.
13. Moorman PG, Schildkraut JM, Calingaert B, et al., Ovulation and ovarian cancer: a comparison of two methods for calculating lifetime ovulatory cycles (United States). Cancer Causes Control 2002; 13: 807-11.
14. Hillier SG, Rae MT, Gubbay O., Ovulation and ovarian cancer. Adv Exp Med Biol 2008; 617: 171-8.
15. McLaughlin JR, Rosen B, Moody J, et al., Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2. J Natl Cancer Inst 2013; 105: 141-8.
16. Iodice S, Barile M, Rotmensz N, et al., Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. Eur J Cancer 2010; 46: 2275-84.
17. Cibula D, Zikan M, Dusek L, et al., Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis. Expert Rev Anticancer Ther 2011; 11: 1197-207.
18. Gronwald J, Byrski T, Huzarski T, et al., Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland. Breast Cancer Res Treat 2006; 95: 105-9.
19. Adami HO, Hsieh CC, Lambe M, et al., Parity, age at first childbirth, and risk of ovarian cancer. Lancet 1994; 344: 1250-4.
20. Whiteman DC, Siskind V, Purdie DM, et al., Timing of pregnancy and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2003; 12: 42-6.
21. Moorman PG, Calingaert B, Palmieri RT, et al., Hormonal risk factors for ovarian cancer in premenopausal and postmenopausal women. Am J Epidemiol 2008; 167: 1059-69.
22. Risch HA., Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone.[comment]. J Natl Cancer Inst 1998; 90: 1774-86.
23. Rodriguez GC, Walmer DK, Cline M, et al., Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis? J Soc Gynecol Investig 1998; 5: 271-6.
24. Cramer DW., The epidemiology of endometrial and ovarian cancer. Hematol Oncol Clin North Am 2012; 26: 1-12.
25. Casagrande JT, Louie EW, Pike MC, et al., "Incessant ovulation" and ovarian cancer. Lancet 1979; 2: 170-3.
26. Lukanova A, Kaaks R., Endogenous hormones and ovarian cancer: epidemiology and current hypotheses. Cancer Epidemiol Biomarkers Prev 2005; 14: 98-107.
27. Hankinson SE, Danforth K., Ovarian cancer. In:, Schottenfeld D, Fraumeni JF, eds. Cancer epidemiology and prevention, 3rd edn. New York: Oxford University Press, 2006: 1013-26.
28. Cramer DW, Titus-Ernstoff L, McKolanis JR, et al., Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 1125-31.
29. McNeilly AS., Lactational control of reproduction. Reprod Fertil Dev 2001; 13: 583-90.
30. Gates MA, Rosner BA, Hecht JL, et al., Risk factors for epithelial ovarian cancer by histologic subtype. Am J Epidemiol 2010; 171: 45-53.
31. Merritt MA, De Pari M, Vitonis AF, et al., Reproductive characteristics in relation to ovarian cancer risk by histologic pathways. Hum Reprod 2013; 28: 1406-17.
32. Roh MH, Kindelberger D, Crum CP., Serous tubal intraepithelial carcinoma and the dominant ovarian mass: clues to serous tumor origin? Am J Surg Pathol 2009; 33: 376-83.
33. Carlson JW, Miron A, Jarboe EA, et al., Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol 2008; 26: 4160-5.
34. Lee Y, Miron A, Drapkin R, et al., A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 2007; 211: 26-35.
35. Folkins AK, Jarboe EA, Roh MH, et al., Precursors to pelvic serous carcinoma and their clinical implications. Gynecol Oncol 2009; 113: 391-6.
36. Landen CN, Jr, Birrer MJ, Sood AK., Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 2008; 26: 995-1005.
37. Medeiros F, Muto MG, Lee Y, et al., The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 2006; 30: 230-6.
38. Finch A, Shaw P, Rosen B, et al., Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol 2006; 100: 58-64.
39. Jarboe EA, Folkins AK, Drapkin R, et al., Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective. Histopathology 2008; 53: 127-38.
40. Sama AR, Schilder RJ., Refractory fallopian tube carcinoma-current perspectives in pathogenesis and management. Int J Women's Health 2014; 6: 149-57.
41. Hunter DJ, Manson JE, Colditz GA, et al., Reproducibility of oral contraceptive histories and validity of hormone composition reported in a cohort of US women. Contraception 1997; 56: 373-8.
42. Olson JE, Shu XO, Ross JA, et al., Medical record validation of maternally reported birth characteristics and pregnancy-related events: a report from the Children's Cancer Group. Am J Epidemiol 1997; 145: 58-67.
43. Natland ST, Andersen LF, Nilsen TI, et al., Maternal recall of breastfeeding duration twenty years after delivery. BMC Med Res Methodol 2012; 12: 179.
44. Narod SA, Moody JR, Rosen B, et al., Estimating survival rates after ovarian cancer among women tested for BRCA1 and BRCA2 mutations. Clin Genet 2013; 83: 232-7.
45. Kotsopoulos J, Lubinski J, Moller P, et al., Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers. Breast Cancer Res Treat 2014; 143: 579-86.